Gatifloxacin (Zymar)

A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.

Also Known As:

Zymar; Tequin; 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; AM 1155; AM-1155; BMS-206584; CG 5501; Gatifloxacine; BMS 206584; BMS206584; 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-

Networked: 468 relevant articles (81 outcomes, 103 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        Gatifloxacin: 468

Experts

1.	Dolecek, Christiane: 8 articles (06/2017 - 06/2007)
2.	Jones, Ronald N: 8 articles (02/2012 - 09/2002)
3.	Nicholson, Susan C: 8 articles (09/2002 - 06/2002)
4.	Baker, Stephen: 7 articles (06/2017 - 06/2011)
5.	Basnyat, Buddha: 7 articles (06/2017 - 06/2007)
6.	Arjyal, Amit: 6 articles (06/2017 - 06/2007)
7.	Wolbers, Marcel: 6 articles (06/2017 - 06/2011)
8.	Mah, Francis S: 6 articles (01/2011 - 09/2003)
9.	Callegan, Michelle C: 5 articles (11/2021 - 09/2003)
10.	McIlleron, Helen: 5 articles (11/2018 - 12/2007)

Related Diseases

1.	Infections 06/01/2002 - "The magnitude of the 24-h AUC/MIC of gatifloxacin required for efficacy against multiple pathogens varied only fourfold and was not significantly altered by drug resistance or site of infection." 08/18/2008 - "The results indicated that gatifloxacin is still effective against MRSA isolates and might be useful for treatment of less serious MRSA infections but careful monitoring of susceptibility is required." 01/01/2001 - "Gatifloxacin should prove to be a safe and effective agent for a wide variety of infections." 06/01/2002 - "In subsequent studies we used the neutropenic and nonneutropenic murine thigh and lung infection models to determine if the magnitude of the AUC/MIC needed for the efficacy of gatifloxacin varied among pathogens (including resistant strains) and infection sites. " 06/01/2004 - "This single-center, open-label study quantified the time course of sinus sterilization, described gatifloxacin exposure at the infection site, and posed the hypothesis that the use of continuous and quantitative time-related end points may allow for better characterization of drug effect with fewer patients than traditional clinical trial approaches. "
2.	Pneumonia (Pneumonitis) 09/01/2002 - "To evaluate the safety and efficacy of gatifloxacin in adults <65, 65 to 79, or > or =80 years old with community-acquired pneumonia, adult male and female outpatients from general community-based practices were enrolled in an open-label, multicenter, noncomparative study. " 02/01/2003 - "An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers." 08/01/2002 - "Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study." 12/01/2005 - "The clinical effect of gatifloxacin (GFLX) at 200 mg daily (half of common dosage) on bacterial community-acquired pneumonia in the elderly was examined. " 12/01/2005 - "Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly."
3.	Keratitis 01/01/2023 - "RvD1 provided an auxiliary effect in gatifloxacin-treated mice with PA keratitis. " 05/08/2022 - "Advantages of Cubosomal Formulation for Gatifloxacin Delivery in the Treatment of Bacterial Keratitis: In Vitro and In Vivo Approach Using Clinical Isolate of Methicillin-Resistant Staphylococcus aureus." 04/01/2010 - "Topical gatifloxacin 0.3% may be successfully used to treat microbial keratitis resulting from atypical mycobacteria." 06/01/2007 - "Zymar may prove useful for SM and PA keratitis." 04/01/2010 - "Atypical mycobacterium keratitis associated with penetrating keratoplasty: case report of successful therapy with topical gatifloxacin 0.3%."
4.	Chronic Bronchitis 03/01/2003 - "The results of the study show that gatifloxacin is a safe and effective agent for the treatment of patients with chronic bronchitis experiencing an acute infectious exacerbation." 01/01/2007 - "Based on the findings of this study in small numbers of healthy young adult volunteers and patients with chronic bronchitis, BMS appears to be a promising method for measuring drug concentrations and determining the pharmacokinetic profile of gatifloxacin in bronchial ELF. " 01/01/2007 - "Bronchial ELF samples were obtained by BMS at 1, 2, 3, 4, 6, 10, and 24 hours after administration of a single oral dose of gatifloxacin 200 mg in healthy young adult (aged 20-25 years) subjects, and at 1, 2, 4, and 10 hours after a single dose in patients with chronic bronchitis (aged > or =20 years). " 01/01/2007 - "BMS and BAL were used to analyze the pharmacokinetics of gatifloxacin in bronchial ELF from healthy young adult subjects and adult patients with chronic bronchitis. " 01/01/2007 - "Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage."
5.	Urinary Tract Infections (Urinary Tract Infection) 10/01/1992 - "AM-1155 also had good efficacy against mouse ascending urinary tract infections with Escherichia coli and P. " 03/01/2000 - "These results suggest that gatifloxacin may be useful in the treatment of urinary tract infections." 08/01/2006 - "Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice." 03/01/2006 - "A 48-year-old man participating in a residential treatment program was treated with gatifloxacin for a urinary tract infection. " 01/01/2004 - "She was given gatifloxacin for a urinary tract infection. "

Related Drugs and Biologics

1.	Moxifloxacin (Avelox)
2.	Ciprofloxacin (Cipro)
3.	Levofloxacin (Levaquin)
4.	Ophthalmic Solutions (Eye Drops)
5.	Fluoroquinolones
6.	Gatifloxacin (Zymar)
7.	Quinolones
8.	Anti-Bacterial Agents (Antibiotics)
9.	Ofloxacin (Ofloxacine)
10.	besifloxacin

Related Therapies and Procedures

1.	Therapeutics
2.	Topical Administration
3.	Duration of Therapy
4.	Laser In Situ Keratomileusis (LASIK)
5.	Dry Powder Inhalers